Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)
10 August 2020 - 8:07PM
Edgar (US Regulatory)
Filed Pursuant
to Rule 424(b)(3)
Registration
Statement No. 333-225995
Prospectus Supplement No. 3
(to Prospectus dated September 28,
2018, Prospectus Supplement No. 1 dated August 2, 2019 and Prospectus Supplement No. 2 dated June 25, 2020)
BRAINSTORM CELL
THERAPEUTICS INC.
2,458,201 Shares
of Common Stock
This prospectus
supplement, together with the prospectus listed above, is to be used by certain holders of the above-referenced securities or by
their pledgees, donees, transferees or other successors-in-interest in connection with the offer and sale of such securities.
This prospectus
supplement updates and should be read in conjunction with the prospectus dated September 28, 2018 (as supplemented to date), which
is to be delivered with this prospectus supplement. Such documents contain information that should be considered when making your
investment decision. To the extent there is a discrepancy between the information contained herein and the information in the prospectus,
the information contained herein supersedes and replaces such conflicting information.
This prospectus
supplement consists of the below supplement to the Selling Securityholders of the prospectus.
Our common stock
is traded on the Nasdaq Capital Market, under the symbol “BCLI”. On August 5, 2020, the last reported sales price for
our common stock was $13.11 per share.
Investing in
the Company’s securities involves risks. See “Risk Factors” beginning on page 5 of the Prospectus, as supplemented
or amended by the prospectus supplements filed to date, to read about factors you should consider.
NEITHER THE
SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR PASSED
UPON THE ADEQUACY OR ACCURACY OF THIS PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.
The date of this
Prospectus Supplement No. 3 is August 6, 2020
The Selling Securityholders table on page 7 of the Prospectus
is supplemented by including the following additional information:
|
|
Securities Beneficially
Owned
Prior to the Offering
|
|
|
Securities Offered Hereby
|
|
|
Securities Beneficially
Owned After this
Offering
|
|
|
Percentage of Common Stock
Owned After this Offering
|
Name
|
|
Common
Stock
|
|
|
Warrants
|
|
|
Common
Stock
|
|
|
Common
Stock
underlying
Warrants
|
|
|
Common
Stock
|
|
|
Warrants
|
|
|
|
OTA LLC
|
|
|
—
|
|
|
|
20,001
|
**
|
|
|
—
|
|
|
|
20,001
|
**
|
|
|
—
|
|
|
|
—
|
|
|
*
|
OTA LLC
|
|
|
—
|
|
|
|
20,000
|
***
|
|
|
—
|
|
|
|
20,000
|
***
|
|
|
—
|
|
|
|
—
|
|
|
*
|
* Less than 1%
** Consists of Warrants assigned and transferred to OTA LLC,
previously held by Selling Securityholder Dr. Joshua A. Hirsch.
*** Consists of Warrants assigned and transferred to OTA LLC,
previously held by Selling Securityholder Maxim Partners LLC.
Brainstorm Cell Therapeu... (NASDAQ:BCLI)
Historical Stock Chart
From Apr 2024 to May 2024
Brainstorm Cell Therapeu... (NASDAQ:BCLI)
Historical Stock Chart
From May 2023 to May 2024